Drug Trial Radar · NCT02414139
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Last checked: Nov 19, 2026Latest source record: Mar 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
373
Actual
Start
Jun 11, 2015
Primary completion
Apr 12, 2023
Study completion May 16, 2023
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 10, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study to evaluate the efficacy and safety of capmatinib as a single-agent treatment for subjects with advanced/metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) who had wild-type epidermal growth factor receptor (EGFR wt) (for exon 19 deletions and exon 21 L858R substitution mutations), anaplastic lymphoma kinase (ALK)-negative rearrangement, and mesenchymal epithelial transition (MET) mutations leading to exon 14 deletion (referred to as MET mutation hereafter) and/or MET amplification.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
CapmatinibDrug
Capmatinib was administered orally, at a dose of 400 mg on a continuous twice daily dosing schedule. Capmatinib was administered to participants in Cohorts 1a, 1b, 2, 3, 4, 5a and 5b in a fasted state. For Cohorts 6.1. 6.2 and 7, capmatinib was administered either with or without food.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) by Blinded Independent Review Committee (BIRC) AssessmentTime frame: Up to approximately 5 years
Locations
95 sites in 20 countries. Site status is shown where the registry gives one.
Pacific Shores Medical Group SC
Long Beach, California
University Of California Los Angeles Dept of Onc
Los Angeles, California
University of California Irvine Medical Center Chao Family Chao Family Comp Cancer Center
Orange, California
H Lee Moffitt Cancer Center and Research Institute .
Tampa, Florida
University of Iowa Hospitals and Clinics SC-3
Iowa City, Iowa
Massachusetts General Hospital MGH Cancer Center
Boston, Massachusetts
VA Ann Arbor Health System VA Ann Arbor Health System
Ann Arbor, Michigan
Mayo Clinic Rochester .
Rochester, Minnesota
Oregon Health and Science University SC
Portland, Oregon
Lehigh Valley Health Network SC
Allentown, Pennsylvania
Andrew and Patel Associates
Camp Hill, Pennsylvania
Mays Cancer Ctr Uthsa Mdacc SC-5
San Antonio, Texas
University of Utah / Huntsman Cancer Institute Oncology
Salt Lake City, Utah
Novartis Investigative Site
La Rioja, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires F.D., Argentina
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Clermont-Ferrand, France
Novartis Investigative Site
La Tronche, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Pierre-Bénite, France
Novartis Investigative Site
Rennes, France
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Marseille, Bouches Du Rhone, France
Novartis Investigative Site
Dijon, Cote D Or, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Göttingen, Germany
Novartis Investigative Site
Halle, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Homburg, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Nuremberg, Germany
Novartis Investigative Site
Ravensburg, Germany
Novartis Investigative Site
Tübingen, Germany
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.